Fennec Pharmaceuticals Inc. (FENC)

Fennec Pharmaceuticals' stock experienced several notable events over the past six months. The company reported Q2 2025 financial results on August 14, 2025, achieving total net revenues of $9.7 million. On November 13, 2025, Fennec reported its Q3 2025 earnings, posting an EPS of -$0.02, surpassing analysts' expectations, and marking its strongest quarter in history with record net product sales of $12.5 million. Also in November 2025, Fennec announced the pricing of an underwritten public offering of common shares at $7.50 per share to repurchase and redeem certain indebtedness. As of December 31, 2025, the stock price was $7.70 per share, reflecting a 22.42% increase from January 2, 2025, but it fell by -1.60% on January 6, 2026, and was down by -3.66% over the preceding 10 days. Overall, the stock's performance over the last six months shows a -14.14% change, with negative insider sentiment due to open-market selling from key executives.

While there is no explicit information detailing demand seasonality for Fennec Pharmaceuticals' products, the company has noted "seasonal spending patterns in the first quarter of the year" which contributed to a decrease in cash during Q1 2025. Net product sales have shown consistent growth across quarters, indicating a general upward trend in product sales rather than a clear seasonal fluctuation in demand.

Fennec Pharmaceuticals is focused on developing and commercializing therapies to prevent cisplatin-induced hearing loss in pediatric cancer patients. Their core business revolves around PEDMARK (sodium thiosulfate injection), which reduces the risk of ototoxicity associated with cisplatin chemotherapy in children. PEDMARK received FDA approval in September 2022, and PEDMARQSI, the brand name for the product in Europe, the UK, Australia, and New Zealand, received European Commission approval in June 2023 and UK approval in October 2023. The company sells its products through regional pediatric oncology specialists and medical science liaisons.

Fennec Pharmaceuticals principally operates in the United States, with its headquarters in Durham, North Carolina. It has expanded internationally through an exclusive licensing agreement with Norgine Pharmaceuticals Ltd., which commercializes PEDMARQSI in Europe, the UK, Australia, and New Zealand. PEDMARQSI is commercially available in the UK and Germany, with plans for additional launches across Europe. The company is also anticipating results from a Japan clinical trial (STS-J01) in the second half of 2025.

Fennec Pharmaceuticals has demonstrated positive momentum through its refined sales strategy and enhanced patient support services, known as Fennec HEARS™. The successful initial uptake of PEDMARQSI® in the UK and Germany has also contributed positively. There is growing confidence in PEDMARK®'s clinical value and its potential to become the standard of care for preventing cisplatin-induced ototoxicity. The company's efforts to expand formulary adoption within large provider networks and build support infrastructure further bolster its reputation.

Fennec Pharmaceuticals, Inc. is primarily owned by institutional shareholders (49.31%) and company insiders (1,220.45%), with retail investors holding 0.00%. The company has 159 institutional owners and shareholders who collectively hold 14,945,152 shares. Major institutional owners include Southpoint Capital Advisors LP, Solas Capital Management, LLC, Rosalind Advisors, Inc., BlackRock, Inc., Vanguard Group Inc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, AIGH Capital Management LLC, IWM - iShares Russell 2000 ETF, State Street Corp, and Tang Capital Management Llc. Southpoint Capital Advisors LP is also noted as the largest individual shareholder.